BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• 

  Caroline Loew

  Caroline Loew, Ph.D., is chief executive officer of Mural Oncology. Loew’s biopharmaceutical career spans more than 25 years of drug development and commercialization experience.
• 

  Adcomms

  Lexicon Loses FDA Adcomm Vote on Insulin Adjunct for Patients With Type 1 Diabetes

  While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external experts found that the company did not provide enough data to support its drug application.

  November 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Editorial

  Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers

  Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler stocking decisions.

  November 1, 2024

   · 

  3 min read

   · 

  Greg Slabodkin
• 

  GLP-1

  Novo’s Wegovy Comparable to Madrigal’s Rezdiffra in Phase III MASH Trial: Analysts

  In part 1 of the pivotal ESSENCE trial, Novo Nordisk’s weight loss drug Wegovy demonstrated “statistically significant and superior improvement” in liver fibrosis in patients with metabolic dysfunction–associated steatohepatitis.

  November 1, 2024

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Earnings

  BMS Delivers Q3 Beat, Raises 2024 Guidance Amid Strong Demand for Legacy and Newer Drugs

  Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as growth portfolio products such as Abecma, Breyanzi and Reblozyl.

  November 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Regeneron Reports Mixed Q3 Sales as Eylea Franchise Remains Under Pressure

  Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously optimistic about the company’s promising cancer, immunology and genetic medicines pipeline.

  November 1, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year

  November 1, 2024

   · 

  5 min read
• Press Releases

  Alveo Technologies Begins Shipping the First Point-of-Need™ Molecular Test for Avian Influenza in Poultry to the EU

  November 1, 2024

   · 

  4 min read
• Press Releases

  Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases

  November 1, 2024

   · 

  3 min read
• Press Releases

  Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

  November 1, 2024

   · 

  6 min read